source
- Nuvig Therapeutics pauses CIDP trial of NVG-2089, cites enrollment and cost challengesNuvig Therapeutics, backed by major pharmaceutical partners, announced it is stopping development of its lead fusion protein NVG-2089 for chronic inflammatory demyelinating polyradiculoneuropathy (…
- FDA approves first expandable pediatric pulmonary heart valveThe FDA has cleared a new surgically implanted pulmonary valve designed for children with congenital pulmonary valve disease. The device, called the Autus Size-Adjustable Valve, was developed by E…